Jump to content

Catalent: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m v2.02b - Bot T12 - WP:WCW project (Punctuation in link)
Cleovulcan (talk | contribs)
206 edits
FDA approval on migraine treatment drug
Line 51: Line 51:
In May 2019, it was announced by Confirmit that Catalent had won the Judges' Choice Award for Voice of the Customer in the Achievement in Customer Excellence category.<ref>{{Cite web|url=https://martechseries.com/sales-marketing/customer-experience-management/confirmit-announces-2019-ace-award-winners/|title=Confirmit Announces 2019 ACE Award Winners|date=2019-05-14|website=MarTechSeries|language=en-US|access-date=2019-09-20}}</ref> In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO<ref>{{Cite web|url=https://endpts.com/its-a-growth-play-catalent-acquires-bristol-myers-european-launch-pad-expanding-global-cdmo-ops/|title='It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops|website=Endpoints News|language=en|access-date=2019-10-18}}</ref> and announced its OneBio Suite for biologic drugs at the BIO International Convention.<ref>{{Cite web|url=https://www.outsourcing-pharma.com/Article/2019/06/03/Catalent-unveils-OneBio-Suite-for-biologics-development|title=Catalent unveils OneBio Suite for biologics development|last=outsourcing-pharma.com|website=outsourcing-pharma.com|language=en-GB|access-date=2019-09-06}}</ref> The same month, Catalent entered a partnership with Iveric Bio to manufacture gene therapy products.<ref>{{Cite web|url=https://www.manufacturingchemist.com/news/article_page/Catalent_chooses_Iveric_Bio_for_AAV_vector_manufacturing/155532|title=Iveric Bio chooses Catalent for AAV vector manufacturing|website=www.manufacturingchemist.com|access-date=2020-01-06}}</ref> In November 2019, Catalent's CEO John Chiminski was awarded CPhI Pharma's "Lifetime Achievement" award.<ref>{{Cite web|url=https://awards.cphi.com/winners/2019-winners/|title=CPhI Pharma Awards 2019 - Recognising Excellence in Pharma|website=awards.cphi.com|language=en-US|access-date=2019-12-19}}</ref> In January 2020, Karen Flynn was appointed as President of Biologics and [[Chief commercial officer|CCO]]; Mike Riley as North America Region President; and Manja Boerman as Europe Region President.<ref>{{Cite news|url=https://www.wsj.com/articles/PR-CO-20200116-911168|title=Catalent Further Strengthens Biologics Business with Key Senior Appointments|last=|first=|date=16 January 2020|work=The Wall Street Journal|access-date=|url-status=live}}</ref>
In May 2019, it was announced by Confirmit that Catalent had won the Judges' Choice Award for Voice of the Customer in the Achievement in Customer Excellence category.<ref>{{Cite web|url=https://martechseries.com/sales-marketing/customer-experience-management/confirmit-announces-2019-ace-award-winners/|title=Confirmit Announces 2019 ACE Award Winners|date=2019-05-14|website=MarTechSeries|language=en-US|access-date=2019-09-20}}</ref> In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO<ref>{{Cite web|url=https://endpts.com/its-a-growth-play-catalent-acquires-bristol-myers-european-launch-pad-expanding-global-cdmo-ops/|title='It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops|website=Endpoints News|language=en|access-date=2019-10-18}}</ref> and announced its OneBio Suite for biologic drugs at the BIO International Convention.<ref>{{Cite web|url=https://www.outsourcing-pharma.com/Article/2019/06/03/Catalent-unveils-OneBio-Suite-for-biologics-development|title=Catalent unveils OneBio Suite for biologics development|last=outsourcing-pharma.com|website=outsourcing-pharma.com|language=en-GB|access-date=2019-09-06}}</ref> The same month, Catalent entered a partnership with Iveric Bio to manufacture gene therapy products.<ref>{{Cite web|url=https://www.manufacturingchemist.com/news/article_page/Catalent_chooses_Iveric_Bio_for_AAV_vector_manufacturing/155532|title=Iveric Bio chooses Catalent for AAV vector manufacturing|website=www.manufacturingchemist.com|access-date=2020-01-06}}</ref> In November 2019, Catalent's CEO John Chiminski was awarded CPhI Pharma's "Lifetime Achievement" award.<ref>{{Cite web|url=https://awards.cphi.com/winners/2019-winners/|title=CPhI Pharma Awards 2019 - Recognising Excellence in Pharma|website=awards.cphi.com|language=en-US|access-date=2019-12-19}}</ref> In January 2020, Karen Flynn was appointed as President of Biologics and [[Chief commercial officer|CCO]]; Mike Riley as North America Region President; and Manja Boerman as Europe Region President.<ref>{{Cite news|url=https://www.wsj.com/articles/PR-CO-20200116-911168|title=Catalent Further Strengthens Biologics Business with Key Senior Appointments|last=|first=|date=16 January 2020|work=The Wall Street Journal|access-date=|url-status=live}}</ref>


In January 2020, Catalent purchased a manufacturing facility located in [[Anagni]], Italy, from [[Bristol-Myers Squibb]]. The site will be used to manufacture and package biologic and oral solid dose products for multiple companies.<ref>{{Cite news|url=https://www.outsourcing-pharma.com/Article/2020/01/13/Bristol-Myers-offloads-manufacturing-plant-to-Catalent|title=Bristol-Myers offloads manufacturing plant to Catalent|last=|first=|date=13 January 2020|work=Outsourcing-Pharma|access-date=|url-status=live}}</ref> In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.<ref>{{Cite news|url=https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo|title=Catalent laying out $315M to snatch another gene therapy CDMO|last=|first=|date=|work=FiercePharma|access-date=3 February 2020|url-status=live}}</ref><ref>{{Cite news|url=https://www.manufacturingchemist.com/news/article_page/Catalent_adds_to_regenerative_therapy_portfolio_with_315m_acquisition/162009|title=Catalent adds to regenerative therapy portfolio with $315m acquisition|last=|first=|date=3 February 2020|work=Manufacturing Chemist|access-date=|url-status=live}}</ref>
In January 2020, Catalent purchased a manufacturing facility located in [[Anagni]], Italy, from [[Bristol-Myers Squibb]]. The site will be used to manufacture and package biologic and oral solid dose products for multiple companies.<ref>{{Cite news|url=https://www.outsourcing-pharma.com/Article/2020/01/13/Bristol-Myers-offloads-manufacturing-plant-to-Catalent|title=Bristol-Myers offloads manufacturing plant to Catalent|last=|first=|date=13 January 2020|work=Outsourcing-Pharma|access-date=|url-status=live}}</ref> In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.<ref>{{Cite news|url=https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo|title=Catalent laying out $315M to snatch another gene therapy CDMO|last=|first=|date=|work=FiercePharma|access-date=3 February 2020|url-status=live}}</ref><ref>{{Cite news|url=https://www.manufacturingchemist.com/news/article_page/Catalent_adds_to_regenerative_therapy_portfolio_with_315m_acquisition/162009|title=Catalent adds to regenerative therapy portfolio with $315m acquisition|last=|first=|date=3 February 2020|work=Manufacturing Chemist|access-date=|url-status=live}}</ref> In March 2020, the [[Food and Drug Administration|U.S. Food and Drug Administration]] (FDA) approved Nurtec ODT, a migraine treatment drug developed by Biohaven and manufactured by Catalent. The drug utilizes Catalent’s Zydis oral disintegrating technology.<ref>{{Cite web|url=https://www.outsourcing-pharma.com/Article/2020/03/19/Migraine-treatment-by-Biohaven-and-Catalent-gets-FDA-approval|title=FDA approves migraine drug formulated for fast dispersion|last=|first=|date=|website=Outsourcing Pharma|language=en-GB|url-status=live|archive-url=|archive-date=|access-date=2020-04-20}}</ref>


In 2020, Catalent was recognized as a certified Top Employer in the United States by the Top Employers Institute.<ref>{{Cite web|url=https://www.top-employers.com/en-US/companyprofiles/us/catalent-pharma-solutions/|title=Catalent Pharma Solutions|website=Top Employers Institute|access-date=2020-03-26}}</ref>
In 2020, Catalent was recognized as a certified Top Employer in the United States by the Top Employers Institute.<ref>{{Cite web|url=https://www.top-employers.com/en-US/companyprofiles/us/catalent-pharma-solutions/|title=Catalent Pharma Solutions|website=Top Employers Institute|access-date=2020-03-26}}</ref>

Revision as of 19:33, 20 April 2020

Catalent, Inc.
Company typePublic company
NYSE: CTLT
S&P 400 Component
IndustryPharmaceuticals
PredecessorCardinal Health PTS
Founded2007
HeadquartersSomerset, New Jersey, US
Number of locations
39 (2019)[1]
Key people
John Chiminski
(Chair, CEO),
Alessandro Maselli
(President, COO),
Wetteny Joseph
(Executive Vice President, CFO)
ServicesDrug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
RevenueUS$2,518.0 million (2019)[1]
US $273.9 million (2019)[1]
US $137.4 million (2019)[1]
Number of employees
12,000 (2019)[1]
Websitewww.catalent.com

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in Somerset, New Jersey. It is a global provider of advanced delivery technologies, development, drugs manufacturing, biologics, gene therapies and consumer health products. It has over 85 years of experience serving the industry, and employs more than 12,000 people, including approximately 2,400 scientists and technicians around the world. In fiscal year 2019 it generated over $2.5 billion in annual revenue.[2]

Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the Pharmaceutical Technologies and Services (PTS) segment of Cardinal Health, Inc.[3] Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998.[4]

In 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).

History

Before 2007

In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania).[5] PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging.[6]

In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan).[7] Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process.[8] The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.),[5] whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market.[8]

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise.[5] In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Madison, Wisconsin).[5] In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe.[5]

In the years between 2004-2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple other acquisitions.[5]

Formation of Catalent in 2007

In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.[3]

After 2007 and initial public offering

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore.[9] Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.[7][10][11] In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil.[12]

Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE).[13] The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014.[13]

In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies.[14][15] The acquisition allowed Catalent to expand its portfolio of drug delivery technologies.[14]

In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,[16] and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities.[17] In October 2016, Catalent received the CPhI Pharma Award for Excellence in Pharma: Contract Services and Outsourcing. [18] Catalent joined a partnership with Pfizer in July 2017 to produce ibuprofen using their softgel capabilities.[19] In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing.[20] In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133M deal.[21]

Alessandro Maselli was appointed as President and Chief Operating Officer in 2019, a newly created position within Catalent.[22] Additionally, Ricardo Pravda, Catalent's chief human resources officer, became the first Latino to serve on the company's executive leadership team.[23] In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to one of their facilities in Swindon, UK; and a custom suite for commercial equipment.[24] Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.[25] Cycle Pharmaceuticals also partnered with Catalent in 2019 to utilize their Zydis technology.[26]

In April 2019, Catalent agreed to acquire Paragon Bioservices Inc. for $1.2 billion to expand its gene-therapy manufacturing capabilities.[27] The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer.[28] As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition.[29]

In May 2019, it was announced by Confirmit that Catalent had won the Judges' Choice Award for Voice of the Customer in the Achievement in Customer Excellence category.[30] In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO[31] and announced its OneBio Suite for biologic drugs at the BIO International Convention.[32] The same month, Catalent entered a partnership with Iveric Bio to manufacture gene therapy products.[33] In November 2019, Catalent's CEO John Chiminski was awarded CPhI Pharma's "Lifetime Achievement" award.[34] In January 2020, Karen Flynn was appointed as President of Biologics and CCO; Mike Riley as North America Region President; and Manja Boerman as Europe Region President.[35]

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb. The site will be used to manufacture and package biologic and oral solid dose products for multiple companies.[36] In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development.[37][38] In March 2020, the U.S. Food and Drug Administration (FDA) approved Nurtec ODT, a migraine treatment drug developed by Biohaven and manufactured by Catalent. The drug utilizes Catalent’s Zydis oral disintegrating technology.[39]

In 2020, Catalent was recognized as a certified Top Employer in the United States by the Top Employers Institute.[40]

Financials

Annual Financial Table[1]
# 2016 2017 2018 2019
Sales/Revenue 1.85B 2.08B 2.46B 2.52B
Total Current Assets 3.09B 2.45B 4.53B 6.18B
Net Operating Cash Flow 155.3M 299.5M 374.5M 247.7M

References

  1. ^ a b c d e f "Catalent, Inc. 2019 Annual Report" (PDF). Retrieved 28 January 2020.
  2. ^ "Catalent, inc. 2019 Annual Report" (PDF). Catalent Investors. Retrieved 27 November 2019.{{cite web}}: CS1 maint: url-status (link)
  3. ^ a b "Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group". Dublin, Ohio: Blackstone Group. 10 April 2007.
  4. ^ "Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock". The Wall Street Journal. 19 May 1998. Retrieved 2 December 2019.
  5. ^ a b c d e f "Cardinal Health's timeline -- CardinalHealth.com". CardinalHealth.com. Archived from the original on 11 April 2015. Retrieved 7 April 2015.
  6. ^ "PCI leads the market in healthcare packaging solutions". PCI Services. Retrieved 7 April 2015.
  7. ^ a b "Catalent completes acquisition of R P Scherer Eberbach". Manufacturing Chemist. Manufacturing Chemist. 1 March 2012. Retrieved 7 April 2015.
  8. ^ a b Kuehn, Steven (6 October 2014). "Container Innovation's Prairie Home". Pharmaceutical Manufacturing. Retrieved 7 April 2015.
  9. ^ "Catalent completes Aptuit deal". BioPharma-reporter.com. 20 February 2012. Retrieved 7 April 2015.
  10. ^ Wasserman, Robert (8 September 2016). "2 big companies and 1 small one to target in the pharma/biotech space". TheStreet. Retrieved 9 July 2019.
  11. ^ "Gelita and R.P. Scherer End 60 Year Joint Venture". .foodingredientsfirst.com/. Retrieved 9 July 2019.
  12. ^ Stanton, Dan (10 October 2013). "Catalent's Brazilian acquisition supports global softgel strategy". inPharma-technologist.com. Retrieved 7 April 2015.
  13. ^ a b "Catalent Issues Initial Public Offering". No. 8. PharmTech.com. Pharmaceutical Technology Sourcing and Management. 4 August 2014. Retrieved 7 April 2015.
  14. ^ a b "Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio". Pharmtech.
  15. ^ "Catalent Pharma Solutions acquires Micron Technologies - 2014-11-13". Crunchbase. Retrieved 25 June 2019.
  16. ^ "Catalent out-licenses ADC to Triphase". BioPharma Dive. Retrieved 4 October 2019.
  17. ^ "Catalent Buys Pharmatek and Lands Spray Drying Technology". Pharmaceutical Investing News. 14 September 2016.{{cite news}}: CS1 maint: url-status (link)
  18. ^ "The winners of the 2016 CPhI Pharma Awards". www.cphi-online.com. Retrieved 12 November 2019.
  19. ^ "Pfizer Catalent partnership to manufacture Advil Liqui-Gels Minis". Manufacturing Chemist. 20 July 2017.{{cite news}}: CS1 maint: url-status (link)
  20. ^ "Catalent targets biologics with Cook Pharmica acquisition". Pharmaceutical Commerce. 19 September 2017. Retrieved 21 November 2019.
  21. ^ "Catalent extends expansion with $133M deal for Juniper Pharmaceuticals". FiercePharma. Retrieved 16 August 2019.
  22. ^ "Catalent Names Alessandro Maselli President and Chief Operating Officer". finance.yahoo.com. Retrieved 19 February 2019.
  23. ^ "Ricardo Pravda Catalyzes Talent at Catalent". Hispanic Executive. 30 September 2019. Retrieved 2 January 2020.
  24. ^ "Catalent Invests in Zydis Ultra Commercialization". pharmtech.com.
  25. ^ "Wellness products take off in the growing recreational cannabis market". Marijuana Business Magazine. 1 October 2019. Retrieved 9 December 2019.
  26. ^ "Cycle taps into Catalent's Zydis tech to manufacture four products". in-Pharma Technologist. 31 October 2019. Retrieved 18 February 2020.
  27. ^ Hopkins, Kimberly Chin and Jared S. "Catalent to Buy Paragon Bioservices for $1.2 Billion". WSJ. Retrieved 1 November 2019.
  28. ^ "Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies". FiercePharma. Retrieved 26 November 2019.
  29. ^ "Paragon growing quickly toward 1,000 employees after Catalent acquisition". Baltimore Business Journal. 17 October 2019. Retrieved 23 December 2019.{{cite web}}: CS1 maint: url-status (link)
  30. ^ "Confirmit Announces 2019 ACE Award Winners". MarTechSeries. 14 May 2019. Retrieved 20 September 2019.
  31. ^ "'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops". Endpoints News. Retrieved 18 October 2019.
  32. ^ outsourcing-pharma.com. "Catalent unveils OneBio Suite for biologics development". outsourcing-pharma.com. Retrieved 6 September 2019.
  33. ^ "Iveric Bio chooses Catalent for AAV vector manufacturing". www.manufacturingchemist.com. Retrieved 6 January 2020.
  34. ^ "CPhI Pharma Awards 2019 - Recognising Excellence in Pharma". awards.cphi.com. Retrieved 19 December 2019.
  35. ^ "Catalent Further Strengthens Biologics Business with Key Senior Appointments". The Wall Street Journal. 16 January 2020.{{cite news}}: CS1 maint: url-status (link)
  36. ^ "Bristol-Myers offloads manufacturing plant to Catalent". Outsourcing-Pharma. 13 January 2020.{{cite news}}: CS1 maint: url-status (link)
  37. ^ "Catalent laying out $315M to snatch another gene therapy CDMO". FiercePharma. Retrieved 3 February 2020.{{cite news}}: CS1 maint: url-status (link)
  38. ^ "Catalent adds to regenerative therapy portfolio with $315m acquisition". Manufacturing Chemist. 3 February 2020.{{cite news}}: CS1 maint: url-status (link)
  39. ^ "FDA approves migraine drug formulated for fast dispersion". Outsourcing Pharma. Retrieved 20 April 2020.{{cite web}}: CS1 maint: url-status (link)
  40. ^ "Catalent Pharma Solutions". Top Employers Institute. Retrieved 26 March 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Catalent&oldid=952145782"